However, TTLshort/hyperactivated mTOR ALL characterized in this study is not associated with classical high-risk criteria [6], and signaling hyperactivity and susceptibility to mTOR inhibition might be heterogeneous among different individual leukemias. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.